Á¾¾ç Àü»çüÇÐ ½ÃÀå : Á¦Ç° À¯Çüº°, ¿ëµµº°, ±â¼úº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Tumor Transcriptomics Market, By Product type, By Application, By Technology, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1532778
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 316 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,474,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,401,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,778,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

Á¾¾ç Àü»çüÇÐÀÇ ½ÃÀå ±Ô¸ð´Â 2023³â 57¾ï 9,010¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç 2024³âºÎÅÍ 2032³â±îÁö 10.10%ÀÇ CAGR·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¾¾ç Àü»çüÇÐ ½ÃÀå - ½ÃÀå ¿ªÇÐ

Áø´Ü ¹× ½Å¾à °³¹ßÀÇ ¿¬±¸ °³¹ß Áõ°¡·Î ½ÃÀå ¼ö¿ä ÃËÁø

Àü»çüÇÐ ½ÃÀåÀÇ ¼ºÀåÀº Áø´ÜÇÐ ¹× ½Å¾à °³¹ßÀÇ ¿¬±¸ °³¹ß Áõ°¡, ¾Ï ¹× ½Å°æ±ÙÀ° Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, Àü»çüÇÐÀÇ Àû¿ë È®´ë¿¡ ÀÇÇØ Ȱ¹ßÈ÷ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. Àü»çüÇÐÀº ƯÈ÷ ¾Ï, ´ç´¢º´°ú °°Àº ¸¸¼ºÁúȯÀÇ ¼¼°èÀû ºÎ´ã Áõ°¡¿¡ µû¶ó Áúº´ Áø´ÜÀ» °¡¼ÓÈ­ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, GLOBOCAN 2020 º¸°í¼­¿¡ µû¸£¸é, Àü ¼¼°èÀûÀ¸·Î ¾à 1,920¸¸ ¸íÀÇ ½Å±Ô ¾Ï ȯÀÚ°¡ ¹ß»ýÇϰí 990¸¸ ¸íÀÌ »ç¸ÁÇß½À´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚ ¼öÀÇ Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀº ÁÖ¿ä ½ÃÀå ±â¾÷µéÀÇ Á¦Ç° Ãâ½Ã, »ç¾÷ È®Àå, Á¦ÈÞ, ÀμöÇÕº´¿¡ ÀÇÇØ Å©°Ô °ßÀ뵃 °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 2¿ù Caris Life Sciences´Â Whole Transcriptome Sequencing(WTS)À» Ȱ¿ëÇÑ ÃֽŠÀ¯Àüü ÇÁ·ÎÆÄÀϸµ Á¦Ç°ÀÎ 'MI Transcriptome'À» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ±â¼úÀº ȯÀÚÀÇ Á¾¾ç¿¡ ´ëÇÑ »ó¼¼ÇÑ RNA ÇÁ·ÎÆÄÀϸµÀ» °¡´ÉÇÏ°Ô Çϸç, DNA, RNA, ´Ü¹éÁúÀ» Æò°¡ÇÏ´Â CarisÀÇ Á¾ÇÕÀûÀÎ Á¢±Ù ¹æ½ÄÀ» º¸¿ÏÇÏ¿© Ä¡·á¹ýÀ» Á¤È®ÇÏ°Ô Á¶Á¤ÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ãâ½Ã´Â ½ÃÀå È®´ë¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¶Âù°¡Áö·Î 2020³â 2¿ù Dovetail Genomics´Â Dovetail HiChIP ŰƮ¿Í Micro-C ŰƮ¸¦ Ãâ½ÃÇÏ¿© ¼¼°è °í°´ ±â¹ÝÀ» È®´ëÇÏ°í ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰíÀÚ ÇÕ´Ï´Ù.

Á¾¾ç Àü»çüÇÐ ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ¸Å³â ¾à 10.10%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦Ç° À¯Çüº° ¼¼ºÐÈ­¿¡¼­ Àåºñ´Â 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµÇ¾ú½À´Ï´Ù.

±â¼ú ¼¼ºÐÈ­¿¡ µû¸£¸é, 2023³â ½ÃÄö½Ì ±â¼úÀÌ ÁÖ¿ä À¯ÇüÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ¸·Î ºÎ»óÇß½À´Ï´Ù.

Á¾¾ç Àü»çüÇÐ ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼®:

¼¼°è Á¾¾ç Àü»çüÇÐ ½ÃÀåÀº Á¦Ç° À¯Çü, ¿ëµµ, ±â¼ú ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¦Ç° À¯Çü¿¡ µû¶ó ¼Ò¸ðǰ, Àåºñ, ±âŸ Á¦Ç° µî ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. Á¦Ç° À¯Çüº°·Î´Â Àü»çü ºÐ¼® ¼öÇà¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â Àåºñ°¡ ¾ÐµµÀûÀÎ ÁöÀ§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê, ½Ç½Ã°£ Á¤·® PCR Àåºñ, Â÷¼¼´ë ½ÃÄö½Ì Ç÷§Æû°ú °°Àº Àåºñ´Â µ¥ÀÌÅ͸¦ »ý¼ºÇÏ°í ³ôÀº 󸮷®ÀÇ Àü»çü ºÐ¼®À» ¼öÇàÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ´Â Áúº´ ¸ÞÄ¿´ÏÁòÀ» ±Ô¸íÇϰí, ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°Çϰí, ¸ÂÃãÇü Ä¡·á Àü·«À» °³¹ßÇϰíÀÚ ÇÏ´Â ¿¬±¸ÀÚ ¹× ÀÓ»óÀÇ¿¡°Ô ¸Å¿ì Áß¿äÇϸç, ½ÃÀå¿¡¼­ÀÇ ¿ìÀ§¸¦ È®°íÈ÷ Çϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ±â¼ú¿¡ µû¶ó ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, ½Ç½Ã°£ Á¤·®Àû ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(Q-PCR), ½ÃÄö½Ì ±â¼ú µî ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. ½ÃÄö½Ì ±â¼úÀº °íÇØ»óµµ Àü»çü ºÐ¼®ÀÌ °¡´ÉÇϱ⠶§¹®¿¡ Àü»çü ºÐ¼® ±â¼ú ºÐ¾ß¿¡¼­ ¿ìÀ§¸¦ Á¡Çϰí ÀÖÀ¸¸ç, RNA ½ÃÄö½Ì(RNA-Seq)Àº ¿¬±¸ÀÚµéÀÌ Èñ±ÍÇÑ Àü»çü¸¦ °ËÃâÇϰí, ´ëü ½ºÇöóÀÌ½Ì À̺¥Æ®¸¦ Á¶»çÇϰí, À¯ÀüÀÚ ¹ßÇö ¼öÁØÀ» Á¤È®ÇÏ°Ô Á¤·®È­ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. À¯ÀüÀÚ ¹ßÇö ¼öÁØÀ» Á¤È®ÇÏ°Ô Á¤·®È­ÇÒ ¼ö ÀÖ°ÔÇÔÀ¸·Î½á Àü»çü ¿¬±¸¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. À¯ÀüÀÚ ¹ßÇö ÇÁ·ÎÆÄÀϰú ºÐÀÚ °æ·Î¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÏ´Â ÀÌ ±â¼úÀÇ ´É·ÂÀº ¿¬±¸¿Í ÀÓ»ó ÀÀ¿ë ¸ðµÎ¿¡¼­ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® ÀâÀ¸¸ç ½ÃÀå¿¡¼­ÀÇ ¿ìÀ§¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

Á¾¾ç Àü»çüÇÐ ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®

Áö¿ªÀûÀ¸·Î º¼ ¶§, ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ °ÉÄ£ ±¤È°ÇÑ Áö¿ªÀ» Æ÷°ýÇÕ´Ï´Ù. ÀÌ Áö¿ª ³» °³º° ±¹°¡µéÀº ½ÃÀåÀ» ´õ¿í ¼¼ºÐÈ­ÇÕ´Ï´Ù. ºÏ¹Ì´Â Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·Â, ÀÇ·áºñ ÁöÃâ Áõ°¡, ¾÷°è ¸®´õÀÇ °­·ÂÇÑ Á¸Àç°¨, ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, ÀÇ·á ÀÌÇØ°ü°èÀÚÀÇ °¡¿ë ±â¼ú¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ƯÈ÷ ¹Ì±¹ ³» ½ÃÀå ±â¾÷ÀÇ ³ôÀº ÁýÁßµµ µîÀ¸·Î ÀÎÇØ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¾¾ç Àü»çüÇÐ ½ÃÀå - °æÀï »óȲ:

Á¾¾ç Àü»çüÇÐ ½ÃÀåÀº Á¾¾çÀÇ À¯ÀüÀÚ ¹ßÇö ÆÐÅÏ¿¡ ´ëÇÑ ¿¬±¸ ¹× ºÐ¼®¿¡ ÃÊÁ¡À» ¸ÂÃá ºÐ¾ß¸¦ ¸»ÇÕ´Ï´Ù. ¾Ï¼¼Æ÷ÀÇ Àü»çü¸¦ ÀÌÇØÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â ±â¼ú°ú ¹æ¹ýÀ» Æ÷ÇÔÇϸç, Á¾¾ç »ý¹°ÇÐ, Áúº´ ÁøÇà ¹× ÀáÀçÀû Ä¡·á Ç¥Àû¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡¼­ ±â¾÷µéÀÌ Ã¤ÅÃÇϰí ÀÖ´Â ÁÖ¿ä Àü·«À¸·Î´Â ÷´Ü ½ÃÄö½Ì ±â¼ú °³¹ß, µ¥ÀÌÅÍ °øÀ¯ ¹× ÀÓ»ó½ÃÇèÀ» À§ÇÑ ¿¬±¸±â°ü ¹× Á¦¾à»ç¿ÍÀÇ Çù·Â °ü°è ±¸Ãà, º¹ÀâÇÑ À¯Àüü µ¥ÀÌÅ͸¦ È¿°úÀûÀ¸·Î ÇØ¼®ÇÒ ¼ö ÀÖ´Â »ý¹°Á¤º¸ÇÐ ¿ª·® °­È­ µîÀÌ ÀÖ½À´Ï´Ù. Á¾¾çÇÐ ºÐ¾ßÀÇ ¿¬±¸ ÅõÀÚ Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ Á¢±Ù, À¯Àüü ÇÁ·ÎÆÄÀϸµ¿¡ ±â¹ÝÇÑ Ç¥Àû ¾Ï Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Àü»çüÇÐ ºÐ¾ßÀÇ ´Ù¾çÇÑ ½ÃÀå ÁøÀÔÀÚµéÀº Áúº´ Áø´ÜÀ» À§ÇÑ »õ·Î¿î ±â±â ¹× ±â¼ú Çõ½Å¿¡ Áö¼ÓÀûÀ¸·Î ÁýÁßÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¾¾ç Àü»çüÇÐ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¾¾ç Àü»çüÇÐÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå Á¾¾ç Àü»çüÇÐ »ê¾÷ Á¶»ç

Á¦5Àå Á¾¾ç Àü»çüÇÐ ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå Á¾¾ç Àü»çüÇÐ ½ÃÀå »óȲ

Á¦7Àå Á¾¾ç Àü»çüÇÐ ½ÃÀå - Á¦Ç° À¯Çüº°

Á¦8Àå Á¾¾ç Àü»çüÇÐ ½ÃÀå - ¿ëµµº°

Á¦9Àå Á¾¾ç Àü»çüÇÐ ½ÃÀå - ±â¼úº°

Á¦10Àå Á¾¾ç Àü»çüÇÐ ½ÃÀå - Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - Á¾¾ç Àü»çüÇÐ ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Tumor Transcriptomics Market size was valued at USD 5,790.10 Million in 2023, expanding at a CAGR of 10.10% from 2024 to 2032.

Tumor transcriptomics involves analyzing the gene expression profiles of tumors by examining RNA molecules (transcripts). This method identifies genes that are either over-expressed or under-expressed compared to healthy tissue, revealing the molecular characteristics of tumors. This approach offers insights into how tumors develop, progress, and potential targets for treatment. Tumor transcriptomics is crucial for personalized medicine as it allows for the identification of key mutations driving cancer and facilitates the customization of treatment plans based on the specific transcriptional profile of each tumor.

Tumor Transcriptomics Market- Market Dynamics

Increasing research and development in diagnostics and drug discovery to propel market demand

The growth of the transcriptomics market is being actively driven by increasing research and development in diagnostics and drug discovery, the rising prevalence of chronic diseases like cancer and neuromuscular disorders, and expanding applications of transcriptomics. Transcriptomics plays a crucial role in accelerating disease diagnostics, especially with the growing global burden of chronic diseases such as cancer and diabetes. For example, according to the GLOBOCAN 2020 report, there were approximately 19.2 million new cancer cases and 9.9 million cancer deaths worldwide. This increasing patient population is expected to positively impact market growth. The market growth is anticipated to be significantly driven by product launches, expansions, collaborations, and acquisitions from key market players. For example, in February 2020, Caris Life Sciences introduced its latest genomic profiling offering, MI Transcriptome, which utilizes Whole Transcriptome Sequencing (WTS). This technology enables detailed RNA profiling of patients' tumors, complementing Caris' comprehensive approach that assesses DNA, RNA, and proteins to tailor therapies accurately. Such launches are poised to positively impact market expansion. Similarly, in February 2020, Dovetail Genomics expanded its global reach with the availability of Dovetail HiChIP and Micro-C Kits, aiming to broaden its customer base worldwide and further stimulate market growth.

Tumor Transcriptomics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.10% over the forecast period (2024-2032)

Based on Product type segmentation, instruments was predicted to show maximum market share in the year 2023

Based on technology segmentation, sequencing technologies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Tumor Transcriptomics Market- Segmentation Analysis:

The Global Tumor Transcriptomics Market is segmented on the basis of Product type, Application, Technology, and Region.

The market is divided into three categories based on Product type: Consumables, Instruments, and Other Products. In terms of product types, instruments hold a dominant position due to their critical role in conducting transcriptomic analyses. Instruments such as microarray scanners, real-time quantitative PCR machines, and next-generation sequencing platforms are essential for generating data and performing high-throughput transcriptome analysis. These instruments are pivotal for researchers and clinicians seeking to understand disease mechanisms, identify biomarkers, and develop personalized treatment strategies, thereby solidifying their dominance in the market.

The market is divided into three categories based on technology: Microarray, Real-time Quantitative Polymerase Chain Reaction (Q-PCR) and Sequencing Technologies. In the transcriptomics market, sequencing technologies dominate the technology segment due to their advanced capabilities in analyzing the transcriptome with high resolution. RNA sequencing (RNA-Seq) has revolutionized transcriptomic studies by allowing researchers to detect rare transcripts, study alternative splicing events, and quantify gene expression levels accurately. This technology's ability to provide comprehensive insights into gene expression profiles and molecular pathways has made it indispensable in both research and clinical applications, driving its dominance in the market.

Tumor Transcriptomics Market- Geographical Insights

From a territorial perspective, this market covers a vast geographic area, stretching across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Individual countries within these regions create further market classifications. North America is projected to lead the market, fueled by favorable government initiatives, rising healthcare spending, a robust presence of industry leaders, advanced healthcare infrastructure, heightened awareness among healthcare stakeholders about available technologies, and a high concentration of market players, particularly in the United States.

Tumor Transcriptomics Market- Competitive Landscape:

The Tumor Transcriptomics market refers to the sector focused on the study and analysis of gene expression patterns in tumors. It involves technologies and methodologies aimed at understanding the transcriptome of cancer cells, which can provide insights into tumor biology, disease progression, and potential therapeutic targets. Key strategies adopted by companies in this market include developing advanced sequencing technologies, establishing collaborations with research institutions and pharmaceutical companies for data sharing and clinical trials, and enhancing bioinformatics capabilities to interpret complex genomic data effectively. The market is driven by increasing research investments in oncology, personalized medicine approaches, and the growing demand for targeted cancer therapies based on genomic profiling. Various market participants in the transcriptomics sector continue to focus on innovating new instruments and techniques for disease diagnostics.

Recent Developments:

In August 2021, HTG Molecular Diagnostics, Inc. launched its HTG Transcriptome Panel in the U.S. and Europe. This panel, utilizing HTG EdgeSeq technology, can measure nearly 20,000 mRNA targets and has demonstrated repeatability for diagnosing multiple cancers. These advancements and launches are expected to bolster growth within this segment.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TUMOR TRANSCRIPTOMICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT

10x Genomics

Agilent Technologies Inc.

BGI Genomics

Bio-Rad Laboratories Inc.

Dovetail Genomics

F. Hoffmann-La Roche AG

Fluidigm Corporation

GE Healthcare

Illumina Inc.

Merck KGaA

Natera Inc.

Others

GLOBAL TUMOR TRANSCRIPTOMICS MARKET, BY PRODUCT TYPE - MARKET ANALYSIS, 2019 - 2032

GLOBAL TUMOR TRANSCRIPTOMICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL TUMOR TRANSCRIPTOMICS MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

GLOBAL TUMOR TRANSCRIPTOMICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Tumor Transcriptomics Market Overview

2. Executive Summary

3. Tumor Transcriptomics Key Market Trends

4. Tumor Transcriptomics Industry Study

5. Tumor Transcriptomics Market: COVID-19 Impact Analysis

6. Tumor Transcriptomics Market Landscape

7. Tumor Transcriptomics Market - By Product type

8. Tumor Transcriptomics Market - By Application

9. Tumor Transcriptomics Market - By Technology

10. Tumor Transcriptomics Market- By Geography

11. Key Vendor Analysis- Tumor Transcriptomics Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â